Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
27 hedge funds and large institutions have $54M invested in Trillium Therapeutics Inc. in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
27% more call options, than puts
Call options by funds: $122K | Put options by funds: $96K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 26 → 27 (+1)
2% more capital invested
Capital invested by funds: $53.1M → $54M (+$966K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.33M |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$820K |
| 3 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$599K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$543K |
| 5 |
Morgan Stanley
New York
|
+$493K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$874K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$720K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$203K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$180K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$165K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $1K | +$235 | +31 | +55% |
|
|
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $466 | – | – | – |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$180K | -24,622 | Closed |
|
|
OAM
29
Oxford Asset Management
Oxford,
United Kingdom
| – | -$165K | -22,097 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$144K | -19,898 | Closed |
|
31
Barclays
London,
United Kingdom
| – | -$76K | -10,500 | Closed |
|
TRIL Hedge Fund Activity: Q1 2018 in Review
27 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2018, worth a combined $54M — up 1.8% from $53.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TRIL positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Platinum Investment Management, opening a new position worth an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $874K.
- 27 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2018, up from 26 in Q4 2017.
- Funds reported $54M of Trillium Therapeutics Inc. stock for Q1 2018, up 1.8% quarter-over-quarter.
- 5 funds opened new Trillium Therapeutics Inc. positions in Q1 2018 and 4 closed out, a net change of +1 holder.
- The largest Trillium Therapeutics Inc. buyer in Q1 2018 was Platinum Investment Management, an estimated $1.33M added.
- The largest Trillium Therapeutics Inc. seller in Q1 2018 was Renaissance Technologies, an estimated $874K sold.
Based on aggregated 13F filings for Q1 2018.